Advertisement
OtherDrug Discovery and Translational Medicine

Optimizing IFN alpha therapy against Myeloproliferative Neoplasms

Gurvan Hermange, Paul-Henry Cournède and Isabelle Plo
Journal of Pharmacology and Experimental Therapeutics June 30, 2023, JPET-AR-2022-001561; DOI: https://doi.org/10.1124/jpet.122.001561

Article Information

JPET-AR-2022-001561
DOI 
https://doi.org/10.1124/jpet.122.001561
PubMed 
37391225
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Published online June 30, 2023.

Article Versions

Copyright & Usage 
Copyright © 2023 American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Gurvan Hermange1,
  2. Paul-Henry Cournède1,*, and
  3. Isabelle Plo2,*
  1. 1CentraleSupélec, France
  2. 2Gustave Roussy, France
  1. ↵* Corresponding Author:
    Isabelle Plo, Gustave Roussy, France. E-mail: Isabelle.PLO{at}gustaveroussy.fr
  2. * Corresponding Author; email: paul-henry.cournede{at}centralesupelec.fr

Statistics from Altmetric.com

Article usage

Article usage: June 2023 to December 2023

AbstractFullPdf
Jun 2023901
Jul 20232300116
Aug 202353029
Sep 20232003426
Oct 20234229882
Nov 2023207951
Dec 2023295

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

OtherDrug Discovery and Translational Medicine

Optimizing IFNα therapy in MPN

Gurvan Hermange, Paul-Henry Cournède and Isabelle Plo
Journal of Pharmacology and Experimental Therapeutics June 30, 2023, JPET-AR-2022-001561; DOI: https://doi.org/10.1124/jpet.122.001561
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement